185563-91-1

Usage

Molecular structure

The compound has an isoindole-1,3-dione core with a 2-(1H-imidazol-2-yl) substituent.

Type of molecule

It is a heterocyclic organic molecule.

Potential applications

The compound has potential applications in pharmaceuticals, agrochemicals, and materials science.

Unique properties

The presence of the imidazole group in the molecule confers unique properties that may be important for specific interactions and biological activities.

Importance for scientific research

Understanding the structure and properties of 1H-Isoindole-1,3(2H)-dione, 2-(1H-imidazol-2-yl)- is essential for research and development efforts in various scientific fields.

Upstream product

• 85-44-9 phthalic anhydride 
• 7720-39-0 1H-imidazol-2-amine 

Downstream Products

• 185563-92-2 1Triphenylmethyl-2-phthalimidoimidazole 

Relevant academic research and scientific papers

Isoxazolines as potent antagonists of the integrin α(v)β3

Starting with lead compound 2, we sought to increase the selectivity for α(v)β3-mediated cell adhesion by examining the effects of structural changes in both the guanidine mimetic and the substituent α to the carboxylate. To prepare some of the desired aminoimidazoles, a novel reductive amination utilizing a trityl-protected aminoimidazole was developed. It was found that guanidine mimetics with a wide range of pK(a)'s were potent antagonists of α(v)β3. In general, it appeared that an acylated 2-aminoimidazole guanidine mimetic imparted excellent selectivity for α(v)β3-mediated adhesion versus α(IIb)β3-mediated platelet aggregation, with selectivity of approximately 3 orders of magnitude observed for compounds 3g and 3h. It was also found in this series that the α- substituent was required for potent activity and that 2,6-disubstituted arylsulfonamides were optimal. In addition, the selective α(v)β3 antagonist 3h was found to be a potent inhibitor of α(v)β3-mediated cell migration.

Integrin receptor antagonists

This invention relates to novel heterocycles including 3-?1-?3-(imidazolin-2-ylamino)propyl!indazol-5-ylcarbonylamino!-2-(benzyloxycarbonylamino)propionic acid, which are useful as antagonists of the αv β3 integrin and related cell surface adhesive protein receptors, to pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of cell adhesion, the treatment of angiogenic disorders, inflammation, bone degradation, cancer metastasis, diabetic retinopathy, thrombosis, restenosis, macular degeneration, and other conditions mediated by cell adhesion and/or cell migration and/or angiogenesis.